Skip to content

Psycho-Education with Problem Solving (PEPS) therapy for personality disorder

Psycho-Education with Problem Solving (PEPS) therapy for adults with personality disorder: a community-based randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN70660936
Enrollment
340
Registered
2009-12-03
Start date
2010-08-01
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality disorder Mental and Behavioural Disorders Mixed and other personality disorders

Interventions

Psycho-education combined with problem solving (PEPS) therapy is a complex cognitive-behavioural intervention that integrates individual and group therapies. Psycho-education consists of up to 4 sessi
previous intervention for this point can be found below). Follow-up assessments for all participants will be completed after the initial treatment phase (weeks 5 - 10), immediately after the second

Sponsors

Nottinghamshire Healthcare NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Living in the community 2. Presence of one or more personality disorder, as identified by the International Personality Disorder Examination 3. Aged 18 years or over, either sex 4. Proficiency in spoken English is necessary for trial participation due to the requirements of the interventions used 5. Capacity to provide valid informed consent;Inclusion criteria: 1. Living in the community 2. Presence of one or more personality disorder, as identified by the International Personality Disorder Examination 3. Aged 18 years or over, either sex 4. Proficiency in spoken English is necessary for trial participation due to the requirements of the interventions used 5. Capacity to provide valid informed consent

Exclusion criteria

Exclusion criteria: Current exclusion criteria as of 23/06/2011: 1. Primary diagnosis of major functional psychosis 2. Insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments 3. Currently engaged in psychological treatment for personality disorder, or likely to start such treatment during the trial period 4. Already enrolled in any other trial Previous exclusion criteria: 1. Insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments, as assessed by the Investigator or authorised designee in conjunction with the participants usual care team. This may be a result of psychosis, developmental disability, organic brain disorder, substance use, or any other disorder or disability. 2. Currently engaged in psychological treatment for personality disorder, or likely to start such treatment during the trial period 3. Already enrolled in any other trial;Exclusion criteria: Current exclusion criteria as of 23/06/2011: 1. Primary diagnosis of major functional psychosis 2. Insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments 3. Currently engaged in psychological treatment for personality disorder, or likely to start such treatment during the trial period 4. Already enrolled in any other trial Previous exclusion criteria: 1. Insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments, as assessed by the Investigator or authorised designee in conjunction with the participants usual care team. This may be a result of psychosis, developmental disability, organic brain disorder, substance use, or any other disorder or disability. 2. Currently engaged in psychological treatment for personality disorder, or likely to start such treatment during the trial period 3. Already enrolled in any other trial

Design outcomes

Primary

MeasureTime frame
Social functioning as measured by the Social Functioning Questionnaire (SFQ). This is an 8-item self-report scale, each item scored on a scale from 0 to 3. A reduction (i.e. an improvement) of 2 points or more on the SFQ at 1 year, post-treatment follow-up is the specified clinically significant change.;Social functioning as measured by the Social Functioning Questionnaire (SFQ). This is an 8-item self-report scale, each item scored on a scale from 0 to 3. A reduction (i.e. an improvement) of 2 points or more on the SFQ at 1 year, post-treatment follow-up is the specified clinically significant change.

Secondary

MeasureTime frame
1. Receipt and cost of services post-therapy and at one year follow-up measured by the Client Service Receipt Inventory 2. Scheduled and unscheduled service use post-therapy and at one year follow-up measured by the Client Service Receipt Inventory and a service use record check. 3. Quality of life post-therapy and at one year follow-up measured by the EQ-5D 4. Referrer's ratings of functioning post-therapy and at one year follow-up measured by the Global Assessment of Functioning 5. Anxiety and depression post-therapy and at one year follow-up meaured by the Hospital Anxiety and Depression Scale 6. A rating of the client's self-assessment of problems post-therapy and at one year follow-up;1. Receipt and cost of services post-therapy and at one year follow-up measured by the Client Service Receipt Inventory 2. Scheduled and unscheduled service use post-therapy and at one year follow-up measured by the Client Service Receipt Inventory and a service use record check. 3. Quality of life post-therapy and at one year follow-up measured by the EQ-5D 4. Referrer's ratings of functioning post-therapy and at one year follow-up measured by the Global Assessment of Functioning 5. Anxiety and depression post-therapy and at one year follow-up meaured by the Hospital Anxiety and Depression Scale 6. A rating of the client's self-assessment of problems post-therapy and at one year follow-up

Countries

United Kingdom

Contacts

Public Contact; ;

;

;;

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 28, 2026